Back to search

National and Kapodistrian University of Athens

Έλεγχος διαφοροποίησης των αρχέγονων αιμοποιητικών κυττάρων

Abstract

dc:description

Introduction: Stem cells (SCs) are undifferentiated cells, which possess the unique ability to divide asymmetrically. This division produces an undifferentiated quiescent cell (renewal of SC) along with a progenitor cell in mitosis committed to proliferation and differentiation.There are two kinds of SCs: the embryonic SC and the adult SC. The embryonic SCs are totipotent cells that can generate each and every kind of embryonic and adult cell types in vivo and in vitro, although they cannot support the genesis of an entire organism on their own. The adult multipotent SCs reside within specific tissues of the organism and are pivotal for the lifelong maintenance of cell homeostasis and the regeneration of dysfunctional or damaged tissues.There are two distinct populations of SCs in the bone marrow, the hematopoietic stem cells (HSCs) and the mesenchymal stem cells (MSCs), that might derive from a common primitive blastoid progenitor cell. Hematopoietic stem cells represent only 1 / 10000 - 1 / 100000 of the total blood cells. They are able to interchangeably commit themselves to different cell lineages and are responsible for the maintenance of constitutive hematopoiesis. Their ability of hematopoietic reconstitution is consistent with the expression of CD133, a cell surface antigen and early HSC marker that reacts with the AC133 antibody. The primitive HSCs that react with the AC133 antibody are the AC133+ cells.HSCs can be obtained from various sources, including bone marrow, peripheral blood or cord blood, for clinical purposes. The noninvasive collection of cord blood provides readily available HSCs. However, the limited number of HSC in a single collection and the delay in their engraftment, constrain the use of cord blood in transplantation protocols. The most life threatening risks of allogeneic transplantation are infections and the development of the Graft-versus-Host Disease (GVHD). The current aims of the in vitro culture of cord blood HSCs are to significantly increase the initial HSC dose, reduce the gravity and duration of post transplant neutropenia and thrombocytopenia, and establish novel specific cell therapies for GVHD.Introduction: Stem cells (SCs) are undifferentiated cells, which possess the unique ability to divide asymmetrically. This division produces an undifferentiated quiescent cell (renewal of SC) along with a progenitor cell in mitosis committed to proliferation and differentiation.There are two kinds of SCs: the embryonic SC and the adult SC. The embryonic SCs are totipotent cells that can generate each and every kind of embryonic and adult cell types in vivo and in vitro, although they cannot support the genesis of an entire organism on their own. The adult multipotent SCs reside within specific tissues of the organism and are pivotal for the lifelong maintenance of cell homeostasis and the regeneration of dysfunctional or damaged tissues.There are two distinct populations of SCs in the bone marrow, the hematopoietic stem cells (HSCs) and the mesenchymal stem cells (MSCs), that might derive from a common primitive blastoid progenitor cell. Hematopoietic stem cells represent only 1 / 10000 - 1 / 100000 of the total blood cells. They are able to interchangeably commit themselves to different cell lineages and are responsible for the maintenance of constitutive hematopoiesis. Their ability of hematopoietic reconstitution is consistent with the expression of CD133, a cell surface antigen and early HSC marker that reacts with the AC133 antibody. The primitive HSCs that react with the AC133 antibody are the AC133+ cells.HSCs can be obtained from various sources, including bone marrow, peripheral blood or cord blood, for clinical purposes. The noninvasive collection of cord blood provides readily available HSCs. However, the limited number of HSC in a single collection and the delay in their engraftment, constrain the use of cord blood in transplantation protocols. The most life threatening risks of allogeneic transplantation are infections and the development of the Graft-versus-Host Disease (GVHD). The current aims of the in vitro culture of cord blood HSCs are to significantly increase the initial HSC dose, reduce the gravity and duration of post transplant neutropenia and thrombocytopenia, and establish novel specific cell therapies for GVHD.Objective: The isolation from cord blood of an adequate in number and differentiation potential HSC population.Materials / Methods: 15 cord blood units were collected. They underwent gravity centrifugation followed by the isolation of AC133+ cells using immunomagnetic separation. Cell centrifugation, flow cytometry and semi-solid cultures were performed to characterize the cells. The AC133+ cells obtained were placed in ex vivo expansion and differentiation cultures towards the megakaryocytic, red cell, dendritic cell and mesenchymal cell lineages.Results: All committed progenitor cell lines proliferate as much as 20 times in vitro with the addition of growth factors. In contrast, HSCs remain multipotent for only about a week in culture and then differentiate. Mesenchymal cells can expand remarkably in vitro with growth factors: they expanded about 500 fold in 6 weeks time without signs of senescence of their population.Conclusions: The AC133+ cell, the earliest common primitive HSC, is not only able to self-renew unchanged, but also to differentiate in functional hematopoietic or mesenchymal SCs. We recommend the use of the AC133 positive cell population for the study of the mechanisms of differentiation and self-renewal of HSCs. It is the first time that in vitro differentiation of the cord blood AC133+ cell population was shown to produce both hematopoietic and mesenchymal cells in a uniform study. Despite the adequate proliferation potential of the AC133+ cell population, net growth of the graft’s size is not attained, due to synchronous differentiation. We achieved greater yield (compared to previous investigators) of AC133+ cell differentiation products (hematopoietic and mesenchymal cells) in sufficient numbers for use in cell therapy. Megakaryocytes, dendritic and mesenchymal cells in particular provide very promising clinical applications.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2006

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Soldatou, Alexandra
  • Σολδάτου, Αλεξάνδρα

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/24503

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Soldatou, Alexandra; Σολδάτου, Αλεξάνδρα. Έλεγχος διαφοροποίησης των αρχέγονων αιμοποιητικών κυττάρων. National and Kapodistrian University of Athens, 2006. http://hdl.handle.net/10442/hedi/24503